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Abstract
Introduction The Fibromyalgia Impact Questionnaire (FIQ) is a
commonly used instrument in the evaluation of fibromyalgia (FM)
patients. Over the last 18 years, since the publication of the
original FIQ, several deficiencies have become apparent and the
cumbersome scoring algorithm has been a barrier to
widespread clinical use. The aim of this paper is to describe and
validate a revised version of the FIQ: the FIQR.
Methods The FIQR was developed in response to known
deficiencies of the FIQ with the help of a patient focus group.
The FIQR has the same 3 domains as the FIQ (that is, function,
overall impact and symptoms). It differs from the FIQ in having
modified function questions and the inclusion of questions on
memory, tenderness, balance and environmental sensitivity. All
questions are graded on a 0–10 numeric scale. The FIQR was
administered online and the results were compared to the same
patient's online responses to the 36-Item Short Form Health
Survey (SF-36) and the original FIQ.
Results The FIQR was completed online by 202 FM patients,
51 rheumatoid arthritis (RA) or systemic lupus erythematosus
(SLE) patients (31 RA and 20 SLE), 11 patients with major
depressive disorder (MDD) and 213 healthy controls (HC). The
mean total FIQR score was 56.6 ± 19.9 compared to a total FIQ
score of 60.6 ± 17.8 (P < 0.03). The total scores of the FIQR
and FIQ were closely correlated (r = 0.88, P < 0.001). Each of
the 3 domains of the FIQR correlated well with the 3 related FIQ
domains (r = 0.69 to 0.88, P < 0.01). The FIQR showed good
correlation with comparable domains in the SF-36, with a
multiple regression analysis showing that the three FIQR domain
scores predicted the 8 SF-36 subscale scores. The FIQR had
good discriminant ability between FM and the 3 other groups;
total FIQR scores were HC (12.1 ± 11.6), RA/SLE (28.6 ±
21.2) and MDD (17.3 ± 11.8). The patient completion time was
1.3 minutes; scoring took about 1 minute.
Conclusions The FIQR is an updated version of the FIQ that
has good psychometric properties, can be completed in less
than 2 minutes and is easy to score. It has scoring
characteristics comparable to the original FIQ, making it
possible to compare past FIQ results with future FIQR results.
Introduction
The Fibromyalgia Impact Questionnaire (FIQ) was developed
in the late 1980s and was first published in 1991 [1], with
minor revisions in 1997 and 2002 [2]. It has subsequently
become one of the most frequently used tools in the evaluation
of fibromyalgia (FM) patients [2-4], being cited in over 300 arti-
cles and translated into 14 languages. Over the 18 years since
its publication, problems in regard to some aspects of its con-Page 1 of 14
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apparent [4-6]. The original questionnaire used a visual analog
scale (VAS) that required patients to slash a 100-mm line and
was scored with a ruler. The scoring was further complicated
by the need to reverse scores in one question and the use of
constants to convert the first 13 questions to a standardized
scale of 0 to 10. The functional questions in the first part of the
FIQ were originally intended for women living in reasonably
affluent countries and assumed the possession of a car, a vac-
uum cleaner, and a washing machine. Moreover, questions
that now are considered relevant, such as dyscognition, ten-
derness, balance, and environmental sensitivity, were not part
of the original FIQ. With these issues in mind, we have devel-
oped an online and paper-equivalent version of the question-
naire: the Revised Fibromyalgia Impact Questionnaire (FIQR)
(Additional data file 1). The FIQR attempts to address the lim-




A draft version of the new questionnaire was constructed by
RMB and tested in a focus group of 10 female patients with
FM (age 58 ± 5.4 years, age range 51 to 68 years; FM dura-
tion 22 ± 12.7 years, duration range 3 to 40 years). The focus
group was guided by RMB with the assistance of KDJ, RLR,
and RW. It was conducted in a manner that encouraged the
free interchange of ideas. The revised questions were based
on previous experience with the FIQ and patients' evaluation
of important symptoms as recorded in OMERACT 8 (Out-
come Measures in Rheumatology) [7], International Classifica-
tion of Functioning, Disability, and Health (ICF) guidelines [8],
and patient surveys from the US [9] and Germany [10]. The
draft modifications of the original FIQ were sixfold: (a) perform
all scoring with 11 boxes (scaled 0 to 10) instead of a mixture
of Likert measurements and VAS measurements; (b) modify
the functional questions (numbers 1 to 11 in the original FIQ);
(c) modify the two impact questions (numbers 12 and 13 in
the original FIQ); (d) expand the symptom questions (numbers
14 to 20 in the original FIQ) to include tenderness, dyscogni-
tion, balance, and environmental sensitivity; (e) simplify the
scoring algorithm; and (f) modify the weighting of the three
domains (function, overall impact, and symptoms) to give more
weight to function. The proceedings were digitally recorded
and transcribed by RW. Following a discussion among
patients and investigators, modifications were made to the
draft version of the FIQR and agreement was reached on the
final version of the FIQR (Table 1). For instance, an original FIQ
question regarding 'walking several blocks' was modified by
the focus group to 'walk continuously for 20 minutes' as the
concept of a block varies from city to city and country to coun-
try. The entirely new question, 'sit in a chair for 45 minutes',
arose out of a discussion on problems associated with pain
and immobility. As it was intended to conduct the validation of
the FIQR online, the use of this collection method and the
validity of using 11 boxes rather than 0- to 100-mm VASs were
compared between the following five versions of the question-
naires that were completed by the focus group: (a) the original
paper version of the FIQ (FIQ-P), (b) an online version of the
FIQ (FIQ-OL), (c) a paper version of the FIQR using 11 boxes
scaled 0 to 10 (FIQR-P), (d) a paper version of the FIQR using
a 100-mm VAS scoring (FIQR-P VAS), and (e) an online ver-
sion of the FIQR (FIQR-OL). The online versions of the FIQR
and FIQ were completed 4 weeks after completion of the
paper versions.
The Revised Fibromyalgia Impact Questionnaire and its 
scoring
The revised FIQ (the FIQR) has 21 individual questions (Table
1). All questions are based on an 11-point numeric rating scale
of 0 to 10, with 10 being 'worst'. As in the FIQ, all questions
are framed in the context of the past 7 days. Following the con-
vention used in the FIQ, the FIQR is divided into three linked
sets of domains: (a) 'function' (contains 9 questions versus 11
in the FIQ), (b) 'overall impact' (contains 2 questions, as in the
FIQ) but the questions now relate to the overall impact of FM
on functioning and the overall impact symptom severity, and
(c) 'symptoms' (contains 10 questions versus 7 in the FIQ);
one original FIQ symptom was dropped: 'When you worked,
how much did pain or other symptoms of your fibromyalgia
interfere with your ability to do your work, including house-
work?' The symptom domain contains four new questions
relating to memory, tenderness, balance, and environmental
sensitivity (to loud noises, bright lights, odors, and cold tem-
peratures). The 'time' dimension is the same as the FIQ; that
is, all questions relate to the impact of FM over the course of
the past 7 days. The scoring of the FIQR is much simpler than
the FIQ: namely, the summed score for function (range 0 to
90) is divided by 3, the summed score for overall impact
(range 0 to 20) is not changed, and the summed score for
symptoms (range 0 to 100) is divided by 2. The total FIQR is
the sum of the three modified domain scores. The weighting of
these three domains is different from the FIQ in that 30% of
the total score is ascribed to 'function' as opposed to 10% in
the FIQ, 50% is ascribed to 'symptoms' as opposed to 70% in
the FIQ, and 'overall impact' remains the same as the FIQ at
20%. The total maximal score of the FIQR remains the same
as the FIQ, namely 100.
Subjects
All of the FM subjects were patients diagnosed within the pre-
vious 5 years with FM as defined by the American College of
Rheumatology (ACR) [11]. They had indicated that they were
interested in being contacted in regard to FM research stud-
ies. The patients with either rheumatoid arthritis or systemic
lupus erythematosus (RA/SLE) were all patients being cur-
rently treated and followed in the clinical practice of BKH;
patients with coexisting FM were excluded initially by pre-
screening the patient charts for a diagnosis of FM and then re-
evaluating each subject prior to entry into the study. ThePage 2 of 14
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patients being currently treated and followed in the clinical
practice of RLR; patients with coexisting FM were excluded as
above. The healthy control group consisted of coworkers,
friends, and relatives; they were requested to email the ques-
tionnaire link to acquaintances whom they considered to be in
good health. All participants completed online informed con-
sent, and the study was conducted in accordance with the
Declaration of Helsinki.
Data collection
The questionnaires were formatted for use on Survey Monkey
(Portland, OR, USA), a commercial online survey technology.
In addition to the FIQR, the original questionnaire (FIQ) and
the 36-Item Short Form Health Survey (SF-36) (Rand Corpo-
ration, Santa Monica, CA, USA) were posted on the Survey
Monkey site for the FM subjects. The SF-36 is a widely used
generic instrument that measures health-related quality of life
[12] and has a well-documented use in the evaluation of FM
patients [13,14]. The online site for the healthy controls and
RA, SLE, and MDD subjects did not contain the FIQ or SF-36
Table 1
The Revised Fibromyalgia Impact Questionnaire
Domain 1 directions: For each of the following nine questions, check the one box that best indicates how much your fibromyalgia made it difficult 
to do each of the following activities over the past 7 days:
Brush or comb your hair No difficulty            Very difficult
Walk continuously for 20 minutes No difficulty            Very difficult
Prepare a homemade meal No difficulty            Very difficult
Vacuum, scrub, or sweep floors No difficulty            Very difficult
Lift and carry a bag full of groceries No difficulty            Very difficult
Climb one flight of stairs No difficulty            Very difficult
Change bed sheets No difficulty            Very difficult
Sit in a chair for 45 minutes No difficulty            Very difficult
Go shopping for groceries No difficulty            Very difficult
Domain 2 directions: For each of the following two questions, check the one box that best describes the overall impact of your fibromyalgia over 
the past 7 days:
Fibromyalgia prevented me from accomplishing goals for the week Never            Always
I was completely overwhelmed by my fibromyalgia symptoms Never            Always
Domain 3 directions: For each of the following 10 questions, check the one box that best indicates the intensity of your fibromyalgia symptoms 
over the past 7 days:
Please rate your level of pain No pain            Unbearable pain
Please rate your level of energy Lots of energy            No energy
Please rate your level of stiffness No stiffness            Severe stiffness
Please rate the quality of your sleep Awoke rested            Awoke very tired
Please rate your level of depression No depression            Very depressed
Please rate your level of memory problems Good memory            Very poor memory
Please rate your level of anxiety Not anxious            Very anxious
Please rate your level of tenderness to touch No tenderness            Very tender
Please rate your level of balance problems No imbalance            Severe imbalance
Please rate your level of sensitivity to loud noises, bright lights, odors, 
and cold
No sensitivity            Extreme sensitivity
Scoring: Step 1. Sum the scores for each of the three domains (function, overall, and symptoms). Step 2. Divide domain 1 score by three, divide 
domain 2 score by one (that is, it is unchanged), and divide domain score 3 by two. Step 3. Add the three resulting domain scores to obtain the 
total Revised Fibromyalgia Impact Questionnaire score.Page 3 of 14
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SLE, and MDD patients differed from the questionnaire for FM
patients in that the term 'health issues' was substituted
throughout the questionnaire for 'fibromyalgia' (this question-
naire, the SIQR, is available in the online version of this article;
Additional data file 2). To ascertain that FM subjects still had
widespread pain and that the healthy controls and RA, SLE,
and MDD patients did not have widespread pain, the question-
naire contained a 'yes/no' item as to the body areas in which
they currently had pain. This item contained 24 separate loca-
tions: left shoulder, right shoulder, left jaw, right jaw, left upper
back, right upper back, left arm, right arm, left hand, right hand,
left lower back, right lower back, left hip, right hip, left thigh,
right thigh, left knee, right knee, left foot, right foot, mid upper
back, mid lower back, front of chest, and neck.
The survey was sent out to 659 FM patients in August 2008,
and 208 responded within 2 weeks (a response rate of 32%).
After approximately 200 FM subjects had completed the ques-
tionnaire, the results were downloaded from the Survey Mon-
key server into Excel spreadsheets (Microsoft Corporation,
Redmond, WA, USA) and the survey was closed to further
participation for the FM patients. The RA/SLE and the MDD
sites were kept open for about 3 months as it was challenging
to find RA, SLE, and MDD patients who did not have wide-
spread pain. The FIQR scoring algorithm was processed on
the Excel spreadsheet and then transferred to STATISTICA
statistical software (StatSoft, Inc., Tulsa, OK, USA) for the sta-
tistical analyses. As a check on data entry and scoring, the
Excel spreadsheet was also loaded into version 14 of SPSS
statistical software (SPSS Inc., Chicago, IL, USA) and the
scoring algorithm was entered into SPSS syntax. Correlation
and verification of the STATISTICA data and results were per-
formed by RW and KDJ.
Data analysis
All data were analyzed in STATISTICA (version 8). Item analy-
sis and questionnaire properties, including domain character-
istics, were evaluated using basic statistics, reliability item
analysis, and Cronbach alpha. Group comparisons on the
mean total FIQR scores and individual FIQR items used one-
way analysis of variance (ANOVA) and multivariate ANOVA for
single and multiple dependent variables, respectively, with
Tukey honestly significantly differences (HSD) post hoc analy-
ses for unequal sample sizes comparing the significance of
specific means. FIQR validity was established using correla-
tional analyses between FIQR, FIQ, and SF-36 items and
domains. Correlations were assessed using Pearson's prod-
uct moment correlation coefficient (r). Multiple regression was
used to establish convergent and discriminant validity. The
three FIQR domains were entered simultaneously as predic-
tors to determine their combined contribution of variance in
SF-36 subscales. Standardized regression coefficients (β)
were calculated to evaluate the unique contribution of the
three FIQR domains to the SF-36 subscales, and the partial
correlation coefficients (pr) were calculated to determine the
correlation of each of the three FIQR domains to the SF-36
subscales after controlling for the other two domains.
Results
Focus group
The focus group tested the relatedness of two versions of the
FIQ (FIQ-P and FIQ-OL) versus three versions of the FIQR
(FIQR-P, FIQR-P VAS, and FIQR-OL). Converting the FIQ to
an online questionnaire did not significantly affect its total
mean scores (59.8 versus 61.8) (Table 2). The use of 11
boxes rather than 0- to 100-mm VASs did not significantly
affect the total mean scores of the paper version of the FIQR
(56.4 versus 57.6). Finally, the online version of the FIQR had
a total score similar to that of the paper version of the FIQ
(59.7 versus 59.8), with a correlation coefficient of 0.83 (P <
0.005). These results provided some confidence that an online
version of the FIQR, with 11-box scoring (0 to 10), would
probably have operating characteristics similar to those of the
well-validated paper version of the original questionnaire (FIQ)
that uses VAS scoring. As the online versions were completed
4 weeks after the paper versions, the similarity of scoring and
Table 2
Focus group total scores and correlations of the various versions of the Fibromyalgia Impact Questionnaire and the Revised 
Fibromyalgia Impact Questionnaire
Mean ± SD FIQ-P FIQR-P FIQR-P VAS FIQ-OL FIQR-OL
FIQ-P 59.8 ± 20.9 - 0.93 0.94 0.91 0.83
FIQR-P 57.6 ± 26.3 0.93 - 0.99 0.94 0.89
FIQR-P VAS 56.4 ± 27.6 0.94 0.99 - 0.94 0.88
FIQ-OL 61.8 ± 21.2 0.91 0.94 0.94 - 0.95
FIQR-OL 59.7 ± 24.9 0.83 0.89 0.88 0.95 -
All correlations were significant at P < 0.001. FIQ-OL, an online version of the Fibromyalgia Impact Questionnaire; FIQ-P, the original paper 
version of the Fibromyalgia Impact Questionnaire; FIQR-OL, an online version of the Revised Fibromyalgia Impact Questionnaire; FIQR-P, a paper 
version of the Revised Fibromyalgia Impact Questionnaire using 11 boxes scaled 0 to 10; FIQR-P VAS, a paper version of the Revised 
Fibromyalgia Impact Questionnaire using a 100-mm visual analog scale scoring instead of 11 boxes; SD, standard deviation.Page 4 of 14
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some evidence for test-retest reliability.
The focus group also completed the SF-36 to compare ease
of use and timing. During the focus group meeting, the FM
patients contributed to the face validity of the final version by
suggesting modifications in wording. For instance, the original
FIQ question regarding 'walking several blocks' was reworded
to 'walk continuously for 10 minutes', 'climb stairs' was modi-
fied to 'climb one flight of stairs', 'make beds' was modified to
'change bed sheets', 'do shopping' was modified to 'go shop-
ping for groceries', and 'vacuum a rug' was modified to 'vac-
uum, scrub, or sweep floors'. The focus group also suggested
two new questions: 'brush or comb your hair' and 'sit in a chair
for 45 minutes'. The 'brush or comb hair' was to be the first
question in the 'function' set as it is usually the least problem-
atic activity for FM patients and would set the difficulty level for
the following eight questions. The results from this focus
group helped to provide some confidence that it would be fea-
sible to use online data collection in that converting the 0- to
100-mm VASs and the Likert questions from the FIQ to an 11-
point numeric rating scale (0 to 10) would not appreciably
compromise the comparison of the FIQR with the FIQ. Patient
completion times for the paper versions of the original FIQ, the
FIQR, and the SF-36 were 2.1 ± 0.03 minutes, 1.3 ± 0.02 min-
utes, and 4.1 ± 0.04 minutes, respectively. The time taken for
investigator scoring of the FIQR was approximately 1 minute.
Analysis of Revised Fibromyalgia Impact Questionnaire 
properties
A total of 208 FM patients completed the online question-
naires (FIQR, FIQ, and SF-36). There were 21 FM subjects
who had fewer than 10 pain locations; on further review of
their pain distribution, 2 subjects did not meet the ACR criteria
for widespread pain and were removed from the survey.
Another four questionnaires were incomplete. Thus, 202 com-
pleted questionnaires were available for analysis. The demo-
graphics of the FM patients and the other three groups are
shown in Table 3. The groups differed in age, F(3,473) =
492.12 (P < 0.001), with FM patients being 8 years older than
healthy controls (P < 0.001). As expected, the four groups dif-
fered substantially in regard to pain locations, F(3,473) =
492.12 (P <0.001), with FM patients having many more pain
locations than the other three groups (all P < 0.001). The total
FIQR scores in the RA (n = 31) and SLE (n = 20) patients
were similar and not significantly different (RA: 28 ± 21.0 and
SLE: 30 ± 22.5, P = 0.74). Hence, the two groups were
merged into a single group (RA/SLE) as the intent was to com-
pare an inflammatory rheumatic disease group with FM. The
healthy group had fewer pain locations than the RA/SLE
groups (P < 0.001), while the MMD group did not differ from
either the healthy controls (P = 0.55) or the RA/SLE (P =
0.29).
The patient FIQR scores, though appearing to be normally dis-
tributed, were negatively skewed (Shapiro-Wilk W = 0.978, P
= 0.003), slightly favoring the more severe cases (Figure 1a).
This FIQR distribution was nearly identical to the distribution
of FIQ scores (Figure 1b), which were also slightly negatively
skewed (Shapiro-Wilk W = 0.980, P = 0.006). The mean
FIQR total score was 56.6 ± 19.9, with a median score of 58
(95% confidence interval [CI] 53.8, 59.4) (Table 4). The mean
FIQ total score was 60.6 ± 17.9, with a median score of 61.9
(95% CI 58.1, 63.0). There were only 12 FM males compared
with 190 FM females, and the respective total FIQR scores
were 53.2 ± 20.4 and 56.8 ± 20.0 (P = 0.55). Higher scores
are indicative of greater dysfunction or symptom severity, and
the FIQR sleep quality question had the highest score (7.61 ±
2.4), followed by tenderness to touch (6.86 ± 2.5), energy
level (6.80 ± 2.4), stiffness (6.72 ± 2.2), environmental sensi-
tivity (6.19 ± 2.9), and pain (6.01 ± 2.1). As expected, 'diffi-
culty with combing hair' had the lowest score (2.42 ± 2.6), but
seven patients had scores of at least 8 on this question. The
Cronbach alpha for the FIQR was 0.95, with item-total corre-
lations ranging from 0.56 to 0.93. The item-total correlations
for the four new items were 0.69 for memory, 0.56 for tender-
ness, 0.65 for balance, and 0.57 for sensitivity, strongly justi-
fying their inclusion as part of the FIQR.
The goal of giving more weight to function in the FIQR appears
to have been successful. Table 5 presents the new weighting
for the three FIQR domains contrasted with the original
weighting in the FIQ (columns 2 and 4). Columns 3 and 5
present the observed (actual) means for the FIQR and FIQ
Table 3
Demographics of fibromyalgia patients and other groups
Fibromyalgia RA/SLE Major depressiona Healthy controls
Number analyzed 202 51 11 213
Age, years 51 ± 10.5 49 ± 13.1a 46 ± 11.4b 43 ± 14.0c
Gender ratio, female/male 16/1 ND 5 ± 1 13 ± 1
Number of pain locations 16 ± 4.9 7.0 ± 4.4 4.0 ± 2.5 1.6 ± 2.3
In comparison with the fibromyalgia patients: aP = 0.25; bP = 0.13; cP < 0.001. ND, not determined; RA/SLE, rheumatoid arthritis/systemic lupus 
erythematosus.Page 5 of 14
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a percentage of the total scores. As can be seen, the 'imbal-
ance' observed in the FIQ between function and symptom (7%
and 74%) has been markedly improved in the FIQR (28% and
53%), approximating the new weighting given to scoring the
FIQR (30% and 50%). The contribution of overall impact to
total score (19% in FIQ and 19% in FIQR) also approximates
the 20% weighting given in each scale. While the new weight-
ing for the FIQR seems to have been successful, there was a
significant 3.99-point difference in the total mean scores (P <
0.03). This may be due to the change in weighting reflected by
a smaller increase in function scores (+11.31) relative to a
greater decrease in symptom scores (-14.85), as shown in col-
umn 6, and/or because of other changes and additions to the
questions in the FIQR.
Convergent validity was assessed by comparing the FIQR to
both the SF-36 and the FIQ. Note that all of the correlations of
the FIQ with the SF-36 are negative due to the fact that higher
scores on the SF-36 relate to being healthier. The SF-36 sub-
scale scores in the FM patients were physical functioning 39.8
± 24.4, physical role 13.5 ± 27.1, emotional role 39.1 ± 43.0,
vitality 17.6 ± 14.3, emotional health 57.4 ± 20.2, social func-
tioning 43.6 ± 32.5, bodily pain 33.9 ± 18.3, and general
health 38.2 ± 21.3. These SF-36 subscale scores were similar
to our previous findings [15] and a review of the literature [13],
helping to confirm that the FM population in this study was
comparable to most other studies. In general, the three
domains of the FIQR and the individual questions correlated
most closely with the corresponding subscales on the SF-36
(Table 6). For instance, the FIQR total score correlated best
with SF-36 physical functioning and pain subscales (r = -0.71
Table 4
Revised Fibromyalgia Impact Questionnaire question values in 202 patients with fibromyalgia
Mean Median One SD -95% CI +95% CI Correlation with total FIQR score Score range
Comb hair 2.4 2 2.6 2.1 2.8 0.62 0–10
Walk for 20 minutes 5.7 6 3.5 5.3 6.2 0.72 0–10
Prepare a meal 4.3 4 3.2 3.9 4.7 0.77 0–10
Clean floors 6.5 7 3.0 6.1 6.9 0.75 0–10
Carry a bag of groceries 5.6 6 3.2 5.2 6.0 0.76 0–10
Climb a flight of stairs 5.6 5 3.3 5.1 6.0 0.80 0–10
Change bed sheets 5.5 6 3.2 5.1 6.0 0.79 0–10
Sit for 45 minutes 5.6 6 3.2 5.1 6.0 0.59 0–10
Go shopping for groceries 5.6 6 3.2 5.2 6.1 0.81 0–10
FIQR function 15.6 15 7.7 14.5 16.7 0.90 0–30
Can't achieve goals 5.7 6 2.9 5.3 6.1 0.85 0–10
Feel overwhelmed 5.2 5 2.9 4.8 5.6 0.86 0–10
FIQR overall 11.0 11 5.4 10.2 11.7 0.91 0–20
Pain rating 6.0 6 2.1 5.7 6.3 0.72 0–10
Energy rating 6.8 7 2.4 6.5 7.1 0.69 0–10
Stiffness rating 6.7 7 2.9 6.4 7.0 0.62 0–10
Sleep quality 7.6 8 2.4 7.3 7.9 0.57 0–10
Depression level 4.6 5 2.9 4.2 5.0 0.60 0–10
Memory problems 5.9 6 2.6 5.6 6.3 0.69 0–10
Anxiety level 4.5 5 3.1 4.0 4.9 0.62 0–10
Tenderness level 6.9 7 2.5 6.6 7.2 0.56 0–10
Balance problems 4.8 5 2.9 4.4 5.2 0.65 0–10
Environmental sensitivity 6.2 7 2.9 5.8 6.6 0.57 0–10
FIQR symptoms 30.0 31 8.8 28.8 31.2 0.93 0–50
FIQR total 56.6 58 20.0 53.8 59.4 - 0–100
CI, confidence interval; FIQR, Revised Fibromyalgia Impact Questionnaire; SD, standard deviation.Page 6 of 14
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36 physical functioning and pain subscales (r = -0.80 and -
0.60), the FIQR overall impact domain correlated best with the
SF-36 physical functioning and pain subscales (r = -0.60 and
-0.64), and the FIQR symptoms domain closely correlated with
all of the SF-36 subscales (r = -0.43 to -0.66). When individual
questions were looked at, the FIQR pain correlated best with
SF-36 pain (r = -0.66), and FIQR anxiety and depression cor-
related best with the SF-36 mental health subscale (r = -0.72
and -0.63).
As the original FIQ is extensively validated through its use in
over 250 studies, we compared FIQR with the original FIQ.
The total score of the FIQR in FM patients was 56.58 ± 20
(range 15 to 97), whereas the total score for the FIQ was
60.56 ± 18.0 (range 10 to 96). While this difference is statis-
tically significant (P = 0.03), the strong correlation of 0.88 (P
< 0.001) between the FIQR and FIQ indicates that patients'
relative standings on the two scales are very similar. This is
indicated by the reasonable correspondence between FM par-
ticipants' scores on the FIQR and FIQ in the scatterplot (Fig-
ure 2). There was a strong correlation of the three domains of
the FIQR plus pain with the corresponding domains of the FIQ
(Table 7). The correlations along the diagonal (r = 0.69 to
0.88), which represents the relation between corresponding
constructs on the new and old scales, are higher than the cor-
Figure 1
Histograms of FIQ and FIQR showing distributions of total scores I  i  istri utions of total scores. (a) The distribution profile of the total Revised Fibromyalgia Impact Questionnaire 
(FIQR) scores in 202 fibromyalgia (FM) patients. (b) The distribution profile of the total Fibromyalgia Impact Questionnaire (FIQ) scores. There is a 
slight negative skewness for both distributions. The FIQR Shapiro-Wilk skewness coefficient (W) is 0.978, and the FIQ Shapiro-Wilk skewness 
coefficient (W) is 0.980.Page 7 of 14
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those below and above the diagonal. This provides further
support for the 'domain' structure of the FIQR.
Multiple regression analysis was used to determine how well
the three FIQR domain scores predicted the eight SF-36
domains (Table 8). In contrast to the correlational analyses
presented in Table 6, multiple regression analysis identified
both the combined and unique variance that predictor varia-
bles contribute to an SF-36 subscale. The three FIQR
domains (function, overall impact, and symptoms) were
entered simultaneously into the regression equation to predict
how much variance in SF-36 domains could be explained by
FIQR components. Column 1 shows the multiple R and com-
bined variance. Columns 2, 3, and 4 identify the FIQR compo-
nents that uniquely predict SF-36 domains. It is seen that all
three FIQR domains contributed collectively and uniquely to all
SF-36 domains. Column 1 shows multiple correlations ranging
from 0.45 to 0.80, with FIQR components collectively explain-
ing 62% of SF-36 physical functioning, 48% of SF-36 pain,
and 30% of SF-36 vitality. Columns 2, 3, and 4 show that the
FIQR domains predicted unique variance in SF-36 domains,
providing good discriminant validity. Overall, FIQR domains
predicted unique variance in 15 of 24 instances, providing
substantial justification for separating the FIQR into three
domains. Notably, FIQR function strongly predicted SF-36
physical functioning and role limitation due to physical health
(column 2) whereas FIQR symptoms predicted each of the
other six remaining SF-36 domains, including SF-36 pain, vital-
ity, emotional health, well-being, and social functioning (col-
umn 4). The FIQR 'overall impact' domain, which assesses
whether FM prevented goals from being accomplished and
whether the patient felt overwhelmed, predicted SF-36 sub-
scales of pain, role limitations due to physical health, emotional
well-being, and social functioning; it did not predict physical
functioning, general health, vitality, or role limitation due to
emotional health. Importantly, each of the three FIQR domains
contributed uniquely to the SF-36 pain subscale, illustrating
that each of the FIQR domains is relevant to the assessment
of pain in FM. In sum, the FIQR, conceptualized around three
linked domains, showed both convergent and discriminant
validity in predicting SF-36 subscales.
Discriminant validity was also evaluated by comparing the
FIQR total scores in FM patients (56.6 ± 19.9, 95% CI 53.8,
59.4) with the scores in healthy controls (12.1 ± 11.6, 95% CI
10.5, 13.6), patients being treated for RA or SLE (28.6 ± 21.2,
95% CI 22.6, 34.5), and patients under treatment for MDD
(17.3 ± 11.8, 95% CI 9.3, 25.2) (Figure 3). As noted in Mate-
rials and methods, the FIQR for these three groups substituted
'health issues' for 'fibromyalgia'. These four total FIQR scores
were significantly different: F(3,473) = 247.94 (P < 0.001).
The FM FIQR total score was significantly higher than in the
three other groups (Tukey HSD test P < 0.001 for all three
comparisons). The FIQR in the RA/SLE group (28.6 ± 21.2)
was significantly higher than in the healthy group (12.1 ± 11.6)
(P < 0.02). The MDD total FIQR score (17.3 ± 12) did not dif-
fer from the healthy and RA/SLE groups.
A similar analysis was conducted to determine whether the FM
group differed from the other three groups on the four new
FIQR symptoms (memory, tenderness, balance, and sensitiv-
ity). If the four new symptoms reflect FM impact, then group
differences on these symptoms should emerge, providing evi-
dence for the construct validity for the syndrome. Figure 4,
which presents the means of all four groups with respect to
each of the four new symptoms, shows that the four groups
discriminated between the four subject groups (Wilks lambda
= 0.33, RaoR(12, 1,243) = 53.86, P < 0.001), with the FM
patients scoring substantially higher than the other three
groups. Additionally, the FM group scored substantially higher
than all three other groups on all four symptoms (P < 0.001),
with the singular exception of the comparison with the MDD
group on memory (P < 0.07). Figure 4 also illustrates the sig-
nificant mean differences on these four symptoms in the FM
group (highest to lowest rankings: tenderness, sensitivity,
memory, and balance). Tenderness, the most problematic
symptom for FM patients, was significantly higher than both
Table 5
Comparison of Fibromyalgia Impact Questionnaire and Revised Fibromyalgia Impact Questionnaire weighting on actual and 
achieved domain scores
FIQ FIQR Change
Given weight Achieved weight Given weight Achieved weight
Function 10% 4.30 (7%) 30% 15.61 (28%) +11.31
Overall impact 20% 11.42 (19%) 20% 10.97 (19%) -0.45
Symptoms 70% 44.85 (74%) 50% 30.00 (53%) -14.85
Total 60.57 (100%) 56.58 (100%) -3.99
This analysis shows that the weighting of the Revised Fibromyalgia Impact Questionnaire (FIQR) closely approximates the given weight. The 
'imbalance' observed in the Fibromyalgia Impact Questionnaire (FIQ) between function and symptom (7% and 74%) has been markedly improved 
in the FIQR (28% and 53%).Page 8 of 14
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Comb hair -0.49 -0.27 -0.11a -0.27 -0.17 -0.24 -0.39 -0.34
Walk for 20 
minutes
-0.78 -0.43 -0.21 -0.25 -0.24 -0.34 -0.55 -0.41
Prepare a 
meal
-0.62 -0.45 -0.30 -0.35 -0.29 -0.46 -0.54 -0.45
Clean floors -0.67 -0.51 -0.33 -0.28 -0.20 -0.43 -0.50 -0.47
Carry a bag of 
groceries
-0.70 -0.46 -0.23 -0.32 -0.18 -0.36 -0.45 -0.41
Climb a flight 
of stairs
-0.78 -0.41 -0.19 -0.35 -0.24 -0.32 -0.51 -0.45
Change bed 
sheets
-0.70 -0.45 -0.23 -0.30 -0.18 -0.34 -0.47 -0.39
Sit for 45 
minutes
-0.34 -0.28 -0.07a -0.27 -0.16 -0.18 -0.32 -0.24
Go shopping 
for groceries
-0.70 -0.47 -0.23 -0.39 -0.26 -0.36 -0.50 -0.46
FIQR function -0.80 -0.51 -0.26 -0.40 -0.27 -0.41 -0.60 -0.49
Goals -0.61 -0.54 -0.34 -0.45 -0.35 -0.50 -0.61 -0.48
Overwhelmed -0.52 -0.42 -0.40 -0.45 -0.49 -0.50 -0.60 -0.46
FIQR overall -0.60 -0.51 -0.39 -0.48 -0.45 -0.53 -0.64 -0.50
Pain rating -0.46 -0.42 -0.23 -0.38 -0.24 -0.37 -0.66 -0.40
Energy rating -0.41 -0.40 -0.26 -0.45 -0.31 -0.32 -0.42 -0.36
Stiffness 
rating
-0.43 -0.35 -0.16 -0.40 -0.22 -0.28 -0.47 -0.30
Sleep quality -0.35 -0.27 -0.27 -0.43 -0.33 -0.37 -0.44 -0.41
Depression 
level
-0.31 -0.25 -0.57 -0.35 -0.73 -0.54 -0.44 -0.41
Memory 
problems
-0.39 -0.32 -0.26 -0.45 -0.38 -0.35 -0.45 -0.39
Anxiety level -0.26 -0.26 -0.47 -0.34 -0.63 -0.55 -0.47 -0.40
Tenderness 
level
-0.38 -0.28 -0.24 -0.31 -0.28 -0.33 -0.47 -0.26
Balance 
problems
-0.49 -0.33 -0.19 -0.35 -0.25 -0.26 -0.50 -0.39
Environmental 
sensitivity
-0.34 -0.26 -0.12a -0.26 -0.19 -0.25 -0.30 -0.34
FIQR 
symptoms
-0.56 -0.46 -0.43 -0.55 -0.54 -0.55 -0.66 -0.54
FIQR total -0.71 -0.54 -0.39 -0.53 -0.46 -0.54 -0.68 -0.57
aThese three correlations under 'emotional role' were not significant. All other correlations were significant: r ≥ 0.15, P < 0.05; r ≥ 0.18, P < 0.01; 
and r ≥ 0.22, P < 0.001. Note: all correlations are negative as the 36-Item Short Form Health Survey (SF-36) scoring has a direction opposite to 
that of the Revised Fibromyalgia Impact Questionnaire (FIQR).
Arthritis Research & Therapy    Vol 11 No 4    Bennett et al.sensitivity (P < 0.004) and memory (P < 0.001). Balance, the
least problematic, was significantly lower than both sensitivity
(P < 0.001) and memory (P < 0.001). Despite these differ-
ences, which contribute to the overall individual differences in
the FIQR total scores, the item-FIQR total correlations for the
four new symptom items (r = 0.56, 0.57, 0.69, and 0.65) were
similar, indicating that they are of nearly equal relevance for
defining the FM syndrome. The RA/SLE group had signifi-
cantly higher scores for the four new symptoms than the
healthy controls (P < 0.001), thus justifying the inclusion of
RA/SLE as an intermediate group.
Discussion
We describe and validate a revised version of the FIQ: the
FIQR. This version was developed in an attempt to correct
some of the problems in the wording, omissions, concepts,
and scoring of the original FIQ [1,2]. There are several modifi-
cations of the FIQ which have been incorporated into the
FIQR, while retaining the basic domain structure in terms of
function, overall impact, and severity of symptoms that are
characteristic of FM (Table 1). Each of the three FIQR domains
was highly correlated with the total FIQR score and predicted
unique variance in SF-36 domains, providing good evidence
for discriminant validity. The mean total score of the FIQR was
approximately 4 points lower than the mean FIQ total score;
we attribute this to the change of the weighting in the scoring
algorithm.
The first domain, function, in the FIQR has been reduced to 9
questions from the original 11 questions and now has a
weighting of 30% of the total score, as opposed to 10% in the
FIQ, to reflect the relative importance of function in assessing
the impact of FM. The specific questions in the function
domain have been modified to reflect a better balance
Table 7
Pearson correlations of major components of the Fibromyalgia Impact Questionnaire with those of the Revised Fibromyalgia 
Impact Questionnaire
FIQ function FIQ overall FIQ pain FIQ symptoms
FIQR function 0.69 0.62 0.59 0.65
FIQR overall 0.56 0.69 0.60 0.75
FIQR pain 0.46 0.55 0.75 0.66
FIQR symptoms 0.54 0.65 0.66 0.88
All correlations were significant at P < 0.001. FIQ, Fibromyalgia Impact Questionnaire; FIQR, Revised Fibromyalgia Impact Questionnaire.
Figure 2
A scatterplot of the total score for the Revised Fibromyalgia Impact Questionnaire (FIQR) and the Fibromyalgia Impact Questionnaire (FIQ) on all 202 fibromyalgia subject  (r = 0.88, P < 0.001)
202 fibromyalgia subjects (r = 0.88, P < 0.001).Page 10 of 14
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and have less gender and ethnicity bias than the FIQ. Impor-
tantly, the FIQR function domain was most highly correlated
with the SF-36 physical functioning subscale. In a multiple
regression model, FIQR function most strongly and uniquely
(that is, after removing shared and unique variance with the
other domains) related to SF-36 physical functioning (Table
8).
The second domain, overall impact, has been completely
revised to reflect two subdomains, namely the overall impact
of FM on functional ability and the overall impact of FM on the
perception of reduced function (Figure 1). The FIQR overall
impact domain was most highly correlated with the SF-36 sub-
scales of physical functioning and pain (Table 6). In a multiple
regression analysis, the overall impact domain was most spe-
cifically associated with the SF-36 subscales of social func-
tioning, role limitation due to physical health, and emotional
well-being. There was a moderately good correlation of the
FIQR overall impact domain with the FIQ overall (Table 8). The
weighting of this FIQR domain remains the same as the FIQ
(that is, 20% of the total score).
The third domain, symptoms, retains the original questions in
the FIQ regarding pain, stiffness, lack of restorative sleep, poor
energy, anxiety, and depression and adds four additional ques-
tions relating to tenderness, memory, balance, and environ-
mental sensitivity (Figure 1). These questions were added in
light of ongoing experience with OMERACT patient delphi
exercises [16], ICF guidelines [8], patient surveys [9], and clin-
ical testing [17]. The weighting for this FIQR domain is 50%
of the total score as opposed to 70% in the FIQ. These four
new symptom questions all had strong correlations with the
total FIQR score, and each provided discriminant validity
between the healthy controls, the patients with RA/SLE, and
the patients with MDD. Furthermore, all four items discrimi-
nated between the four subject groups, with the FM patients
scoring substantially and significantly higher than the other
three groups. The scores on memory were similar in the FM
group and the MDD group, probably an expression of the well-
documented memory problems associated with depressive ill-
ness [18,19]. It is interesting to note that, although the FM and
MDD groups had similar scores on depression and anxiety, the
FM patients had distinctively higher scores on tenderness,
environmental sensitivity, and balance. This was also the case
when comparing the FM with the RA/SLE group. Thus, the FM
Table 8
Multiple regression analysis showing how the three domains of the Revised Fibromyalgia Impact Questionnaire predict subscales 
of the 36-Item Short Form Health Survey
SF-36 subscales (dependent variable) R and R2 predicted by combined FIQR 
domains
FIQR function FIQR overall impact FIQR symptoms
Physical functioning R = 0.80a β = -0.803a β = -0.005 β = 0.015
R2 = 0.62 pr = -0.641a pr = -0.004 pr = 0.014
Role limitation due to physical health R = 0.55a β = -0.270b β = -0.261c β = -0.058
R2 = 0.29 pr = -0.200b pr = -0.167c pr = -0.040
Role limitation due to emotional health R = 0.45a β = 0.170 β = -0.234c β = -0.362d
R2 = 0.19 pr = 0.120 pr = -0.140c pr = -0.237d
Energy/Fatigue R = 0.55a β = 0.029 β = -0.133 β = -0.465a
R2 = 0.30 pr = 0.022 pr = -0.080 pr = -0.312a
Emotional well-being R = 0.58a β = 0.308d β = -0.210c β = -0.593a
R2 = 0.32 pr = 0.231d pr = -0.137c pr = -0.392a
Social functioning R = 0.57a β = 0.066 β = -0.287b β = -0.369d
R2 = 0.32 pr = 0.050 pr = -0.186b pr = -0.256d
Pain R = 0.70a β = -0.175c β = -0.219c β = -0.362a
R2 = 0.48 pr = -0.0152c pr = -0.163c pr = -0.285a
General health R = 0.57a β = -0.185c β = -0.085 β = -0.347d
R2 = 0.31 pr = -0.140c pr = -0.056 pr = -0.241d
aP < 0.0001; bP < 0.01; cP < 0.05; dP < 0.001. First column: adjusted R-square (R2) × 100 indicates the total variance in 36-Item Short Form 
Health Survey (SF-36) subscale accounted for by the common and unique variance in Revised Fibromyalgia Impact Questionnaire (FIQR) 
function, overall, and symptom domains taken together. Multiple regression (R) indicates the size of correlation between three FIQR domains as 
predictors taken together with the SF-36 subscale as criterion. Columns 2, 3, and 4 present the standardized regression (β) coefficients, which 
represent the unique contribution of the predictor variable, and the partial correlation (pr) coefficients, which represent the correlation for the one 
(FIQR) domain with the SF-36 subscale after controlling for the other two (FIQR) domains.Page 11 of 14
(page number not for citation purposes)
Arthritis Research & Therapy    Vol 11 No 4    Bennett et al.patients displayed distinctive responses to these four new
questions.
Although all of the FIQR symptom items and the FIQR symp-
tom domain were correlated with all of the SF-36 subscales,
multiple regression analysis indicated that the symptom
domain provided more unique variance to six of the SF-36 sub-
scales (role limitation due to emotional health, vitality, emo-
tional well-being, social functioning, pain, and general health)
than did the other two FIQR domains. Coupled with the func-
tion domain uniquely predicting SF-36 physical functioning,
this analysis provides substantial discriminant validity for the
domain structure of the FIQR in relation to the SF-36. Each of
the 21 FIQR questions can be related to relevant outcomes as
specified by the ICF guidelines [20] (Table 9). Prodinger and
colleagues [5] reported a closer ICF correspondence
between the FIQ and SF-36 compared with 14 other general
health instruments; thus, the current finding showing a strong
relation between FIQR and the SF-36 provides further confir-
mation of the content validity of the FIQR. However, it is worth
noting that substantial FM variance (column 1 of Table 8) is not
captured by the SF-36, suggesting that the FIQR is measuring
unique variance that is distinctive and specific to the FM syn-
drome.
The use of a numeric rating scale using 11 boxes, scored 0 to
10, in the FIQR as opposed to the combination of Likert and
VAS scaling in the FIQ did not result in significant differences
in the total scores in the focus group analysis (Table 2). Fur-
thermore, there was excellent correlation between the paper
version with VAS scoring (FIQ-P VAS), the paper version
using the 0-to-10 numeric rating (FIQ-P), and the online FIQR
using the 0-to-10 numeric rating (FIQR-OL) (Table 2). The use
of the numeric rating considerably simplifies the scoring algo-
rithm for the FIQR and obviates the need to use a ruler to
measure VAS scores. Furthermore, the use of the numeric rat-
ing scoring greatly simplifies the conversion of a paper version
of the FIQR to an online version, as done in this study. The
paper version of the FIQR took approximately half the time to
complete compared with the FIQ. On the other hand, the SF-
36 took nearly four times as long to complete as the FIQR. Our
favorable experience with the use of a numeric rating scale
compared with continuous VAS scoring reflects the experi-
ence of several other groups [21-23] and is in line with the rec-
ommendations of the Initiative on Methods, Measurement, and
Pain Assessment in Clinical Trials (IMMPACT) [24]. This sim-
plification and greater efficiency should make the FIQR easier
to use by researchers and physicians. The FIQR shows good
ability to discriminate between FM patients and patients with
RA, SLE, and MDD who do not have concomitant FM.
There are several limitations to the interpretation of this study.
The testing was done entirely online; thus, it is not possible to
equate these results with a paper version of the FIQR. How-
ever, a comparison of the paper and online versions was com-
Figure 3
The total Revised Fibromyalgia Impact Questionnaire (FIQR) scores of the 202 fibromyalgia (FM) patients compared with the scores for the 213 he lthy controls, 51 patients with rheumatoid arthritis (RA) r ys-emic lupus erythemat sus (SLE), and 11 patie s with major depres-sion
the 202 fibromyalgia (FM) patients compared with the scores for the 
213 healthy controls, 51 patients with rheumatoid arthritis (RA) or sys-
temic lupus erythematosus (SLE), and 11 patients with major depres-
sion. *Note: a concomitant diagnosis of FM was an exclusion criterion 
for inclusion of RA/SLE and major depressive disorder (MDD) subjects. 
SE, standard error.
Figure 4
A plot of the mean scores for the four new symptoms added to the Revised Fibromyalgia Impact Questionnaire ( emory, tenderness, bal-ance, and environmental ensitivity) against each f the four groups: fibromyalgia (FM), rheu atoid arthritis/syst mi  lupu  rythematosus (RA/SLE), healthy, and m j depres iv  di order (MDD)
Revised Fibromyalgia Impact Questionnaire (memory, tenderness, bal-
ance, and environmental sensitivity) against each of the four groups: 
fibromyalgia (FM), rheumatoid arthritis/systemic lupus erythematosus 
(RA/SLE), healthy, and major depressive disorder (MDD).Page 12 of 14
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differences between the two methods. No test-retest reliability
was performed on the online participants, but again the limited
information from the focus group suggested good test-retest
reliability. Only 12 males completed the questionnaires; thus,
their FIQR scores cannot be considered representative of a
large male population. We were able to recruit only 11 sub-
jects with MDD who did not have FM; thus, the validity of com-
parisons associated with MDD may be limited. We could not
estimate the sensitivity to change of the FIQR or the minimal
clinical important difference (MCID) for scoring the FIQR, as
has been done for the FIQ [25]; these analyses will have to
await the use of the FIQR in a large clinical trial. Given that
there are currently no generally accepted objective measures
of FM severity, validated questionnaires measuring patients'
subjective responses will continue to be important. In this
respect, we hope this revised version of the FIQ will be useful
to both researchers and clinicians.
Conclusions
A revised version of the FIQ, called the FIQR, is described
herein. The FIQR has sound psychometric properties, discrim-
inates between FM patients and patients with RA, SLE, and
MDD, takes just over 1 minute to complete, is easy to score,
and can be used in online surveys. The FIQR has a good cor-
relation with the original FIQ, thus providing the ability to com-
pare the results of studies using the older version with studies
using the revised version.
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